Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
1.430
-0.020 (-1.38%)
At close: Aug 8, 2025, 4:00 PM
1.450
+0.020 (1.40%)
After-hours: Aug 8, 2025, 6:23 PM EDT
Mainz Biomed Revenue
In the year 2024, Mainz Biomed had annual revenue of $893.99K, down -0.17%. Mainz Biomed had revenue of $186.61K in the quarter ending December 31, 2024, a decrease of -13.11%.
Revenue (ttm)
$893.99K
Revenue Growth
-0.17%
P/S Ratio
1.55
Revenue / Employee
$34,384
Employees
26
Market Cap
4.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 893.99K | -1.49K | -0.17% |
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MYNZ News
- 4 days ago - Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewsWire
- 16 days ago - Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies - GlobeNewsWire
- 24 days ago - Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition - GlobeNewsWire
- 6 weeks ago - Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - GlobeNewsWire
- 2 months ago - Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire
- 2 months ago - Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewsWire
- 3 months ago - Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewsWire
- 3 months ago - Mainz Biomed Enters into Technology Partnership with EDX Medical Group - GlobeNewsWire